Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines
- 3 December 2007
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 26 (4), 486-493
- https://doi.org/10.1016/j.vaccine.2007.11.036
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVAVirology, 2008
- Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector VaccinesJournal of Virology, 2007
- Direct Comparison of Antigen Production and Induction of Apoptosis by Canarypox Virus- and Modified Vaccinia Virus Ankara-Human Immunodeficiency Virus Vaccine VectorsJournal of Virology, 2007
- Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccineVaccine, 2006
- Multiprotein HIV Type 1 Clade B DNA and MVA Vaccines: Construction, Expression, and Immunogenicity in Rodents of the MVA ComponentAIDS Research and Human Retroviruses, 2004
- Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in MacaquesAIDS Research and Human Retroviruses, 2004
- Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administrationArchiv für die gesamte Virusforschung, 2003
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeysVaccine, 1998
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal modelVaccine, 1996